|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tenofovir vs lamivudine plus adefovir in chronic hepatitis B:TENOSIMP-B study显示文摘AIM To demonstrate the non-inferiority(15% non-inferiority limit) of monotherapy with tenofovir disoproxil fumarate(TDF) vs the combination of lamivudine(LAM) plus adefovir dipivoxil(ADV) in the maintenance of virologic response in patients with chronic hepatitis B(CHB) and prior failure with LAM.METHODS This study was a Phase IV prospective, randomized, open, controlled study with 2 parallel groups(TDF and LAM+ADV) of adult patients with hepatitis B e antigen(HBe Ag)-negative CHB, prior failure with LAM, on treatment with LAM+ADV for at least 6 mo, without prior resistance to ADV and with an undetectable viral load at the start of the study, in 14 Spanish hospitals. The follow-up time for each patient was 48 wk after randomization, with quarterly visits in which the viral load, biochemical and serological parameters, adverse effects, adherence to treatment and consumption of hospital resources were analysed.RESULTS Forty-six patients were evaluated [median age: 55.4 years(30.2-75.2); 84.8% male], including 22 patients with TDF and 24 with LAM+ADV. During study development, hepatitis B virus DNA(HBV-DNA) remained undetectable, all patients remained HBe Ag negative, and hepatitis B surface antigen(HBs Ag) positive. Alanine aminotransferase(ALT) values at the end of the study were similar in the 2 groups(25.1± 7.65, TDF vs 24.22 ± 8.38, LAM+ADV, P = 0.646). No significant changes were observed in creatinine or serum phosphorus values in either group. No significant differences between the 2 groups were noted in the identification of adverse effects(AEs)(53.8%, TDF vs 37.5%, LAM+ADV, P = 0.170), and none of the AEs which occurred were serious. Treatment adherence was 95.5% and 83.3% in the TDF and the LAM+ADV groups, respectively(P = 0.488). The costs associated with hospital resource consumption were significantly lower with the TDF treatment than the LAM+ADV treatment(€4943 ± 1059 vs €5811 ± 1538, respectively, P < 0.001).CONCLUSION TDF monotherapy proved to be safe and not inferior to the LAM+ADV combination therapy in maintaining virologic response in patients with CHB and previous LAM failure. In addition, the use of TDF generated a significant savings in hospital costs. | Manuel Rodríguez Juan Manuel Pascasio Enrique Fraga Javier Fuentes Martín Prieto Gloria Sánchez-Antolín Jose Luis Calleja Esther Molina María Luisa García-Buey María Angeles Blanco Javier Salmerón María Lucía Bonet Jose Antonio Pons Jose Manuel González Miguel Angel Casado Francisco Jorquera 无 | 2017 | World Journal of Gastroenterology2017，23，41： | 16 |
| 2 | COX-2 in liver,from regeneration to hepatocarcinogenesis:What we have learned from animal models?显示文摘The use of animals lacking genes or expressing genes under the control of cell-specific promoters has signifi cantly increased our knowledge of the genetic and molecular basis of physiopathology,allowing testing of functional hypotheses and validation of biochemical and pharmacologic approaches in order to understand cell function.However,with unexpected frequency,gene knockout animals and,more commonly,animal models of transgenesis give experimental support to even opposite conclusions on gene function.Here we summarize what we learned on the role of cyclooxygenase 2(COX-2) in liver and revise the results obtained in 3 independent models of mice expressing a COX-2 transgene specifi cally in the hepatocyte.Upon challenge with pro-inflammatory stimuli,the animals behave very differently,some transgenic models having a protective effect but others enhancing the injury.In addition,one transgene exerts differential effects on normal liver physiology depending on the transgenic animal model used. | Paloma Martín-Sanz Rafael Mayoral Marta Casado Lisardo Boscá | 2010 | World Journal of Gastroenterology2010，16，12： | 12 |
| 3 | New aspects in celiac disease显示文摘Celiac disease (CD) is a common autoimmune disorder characterized by an immune response to ingested gluten and has a strong HLA association with HLA- DQ2 and HLA-DQ8 molecules, but human HLA-DQ risk factors do not explain the entire genetic susceptibility to gluten intolerance. CD is caused by the lack of immune tolerance (oral tolerance) to wheat gluten. In this sense, the expression of soluble HLA-G in CD is of special interest because the molecule plays an important role in the induction of immune tolerance. The enhanced expression of soluble HLA-G found in CD may be part of a mechanism to restore the gluten intolerance. In this editorial, we review recent progress in understanding CD in relation to its prevalence, diagnosis and possible mechanisms of pathogenesis. | MI Torres MA López Casado A Ríos | 2007 | World Journal of Gastroenterology2007，13，8： | 10 |
| 4 | Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives显示文摘The biosynthesis of prostaglandins and thromboxanes has been a focus of interest in the management of many liver diseases.Cyclooxygenases are the enzymes involved in the first step of the biosynthesis of these lipid mediators and selective inhibitors for these isoenzymes as well as pharmacological analogues of prostaglandins have been developed and are currently applied therapeutically.Here we discuss the implications of these enzymes in the onset of metabolic and lipid disorders in the liver and their potential role in the progression of the diseases towards fibrosis and hepatocellular carcinogenesis. | Paloma Martín-Sanz Marta Casado Lisardo Boscá | 2017 | World Journal of Gastroenterology2017，23，20： | 7 |
| 5 | New approaches in angiogenic targeting for colorectal cancer显示文摘Colorectal carcinoma (CRC) is one of the leading causes of cancer death worldwide. In the last decade, the addition of irinotecan and oxaliplatin to standard fluorouracil-based chemotherapy regimens have set the new benchmark of survival for patients with metastatic CRC at approximately 20 mo. Despite these advances in the management of CRC, there is a strong medical need for more effective and well-tolerated therapies. The dependence of tumor growth and metastasis on blood vessels makes angiogenesis a rational target for therapy. One of the major pathways involved in this process is the vascular endothelial growth factor (VEGF) and its receptors (VEGFR). In 2004, the first agent targeting angiogenesis, bevacizumab (BV), was approved as an adjunct to first-line cytotoxic treatment of metastatic CRC. The role of BV as part of adjuvant treatment and in combination with other targeted therapies is the subject of ongoing trials. However, BV is associated with an increase in the risk of arterial thromboembolic events, hypertension and gastrointestinal perforations and its use must be cautious. Novel VEGFR TK inhibitors with different ranges of nanomolar potencies, selectivities, and pharmacokinetic properties are entering phase Ⅲ trials for the treatment of cancer. Conversely, one of these novel agents, vatalanib, has been shown not to confer survival benefit in first and second-line treatment of advanced CRC. The basis of these findings is being extensively evaluated. Ongoing and new well-designed trials will define the optimal clinical application of the actual antiangiogenic agents, and, on the other hand, intensive efforts in basic research will identify new agents with different antiangiogenic approaches for the treatment of CRC. In this review we discuss and highlight current and future approaches in angiogenic targeting for CRC. | Aleix Prat Esther Casado Javier Cortés | 2007 | World Journal of Gastroenterology2007，13，44： | 6 |
| 6 | Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer:An update显示文摘The biosynthesis of prostanoids is involved in both physiological and pathological processes. The expression of prostaglandin-endoperoxide synthase 2(PTGS2; also known as COX-2) has been traditionally associated to the onset of several pathologies, from inflammation to cardiovascular, gastrointestinal and oncologic events. For this reason, the search of selective PTGS2 inhibitors has been a focus for therapeutic interventions. In addition to the classic non-steroidal anti-inflammatory drugs, selective and specific PTGS2 inhibitors, termed coxibs, have been generated and widely used. PTGS2 activity is less restrictive in terms of substrate specificity than the homeostatic counterpart PTGS1, and it accounts for the elevated prostanoid synthesis that accompanies several pathologies. The main regulation of PTGS2 occurs at the transcription level. In addition to this, the stability of the mRNA is finely regulated through the interaction with several cytoplasmic elements, ranging from specificmicroR NAs to proteins that control mR NA degradation. Moreover, the protein has been recognized to be the substrate for several post-translational modifications that affect both the enzyme activity and the targeting for degradation via proteasomal and non-proteasomal mechanisms. Among these modifications, phosphorylation, glycosylation and covalent modifications by reactive lipidic intermediates and by free radicals associated to the proinflammatory condition appear to be the main changes. Identification of these post-translational modifications is relevant to better understand the role of PTGS2 in several pathologies and to establish a correct analysis of the potential function of this protein in diseases progress. Finally, these modifications can be used as biomarkers to establish correlations with other parameters, including the immunomodulation dependent on molecular pathological epidemiology determinants, which may provide a better frame for potential therapeutic interventions. | Rafael I Jaén Patricia Prieto Marta Casado Paloma Martín-Sanz Lisardo Boscá | 2018 | World Journal of Gastroenterology2018，24，48： | 5 |
| 7 | Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer显示文摘Objective:Long-term survivors(LS)of non-small cell lung cancer(NSCLC)without driver alterations,displaying an overall survival(OS)of more than 3 years,comprise around 10%of cases in several series treated with chemotherapy.There are classical prognosis factors for these cases[stage,Eastern Cooperative Oncology Group(ECOG),etc.],but more data are required in the literature.In this multi-center study,we focused on LS of advanced NSCLC with OS above 36 months to perform a clinical-pathological and molecular characterization.Methods:In the first step,we conducted a clinical-pathological characterization of the patients.Afterwards,we carried out a genetic analysis by comparing LS to a sample of short-term survivors(SS)(with an OS less than 9 months).We initially used whole-genome RNA-seq to identify differentiating profiles of LS and SS,and later confirmed these with reverse transcription-polymerase chain reaction(RT-PCR)for the rest of the samples.Results:A total of 94 patients were included,who were mainly men,former smokers,having adenocarcinoma(AC)-type NSCLC with an ECOG of 0-1.We obtained an initial differential transcriptome expression,displaying 5 over-and 33 under-expressed genes involved in different pathways:namely,the secretin receptor,surfactant protein,trefoil factor 1(T FF1),serpin,Ca-channels,and Tolllike receptor(TLRs)families.Finally,RT-PCR analysis of 40(20 LS/20 SS)samples confirmed that four genes(surfactant proteins and SFTP)were significantly down-regulated in SS compared to LS by using an analysis of covariance(ANCOVA)model:SFTPA1(P=0.023),SFTPA2(P=0.027),SFTPB{P=0.02),and SFT PC(P=0.047).Conclusions:We present a sequential genetic analysis of a sample of NSCLCLS with no driver alterations,obtaining a differential RNA-seq/RT-PCR profile showing an abnormal expression of SF genes. | Juan Moreno-Rubio Santiago Ponce Rosa Alvarez Maria Eugenia Olmedo Sandra Falagan Xabier Mielgo Fatima Navarro Patricia Cruz Luis Cabezon-Gutierrez Carlos Aguado Gonzalo Colmenarejo Marta Munoz-Fernandez de Leglaria Ana Belen Enguita Maria Cebollero Amparo Benito Isabel Alemany Carolina del Castillo Ricardo Ramos Ana Ramirez de Molina Enrique Casado Maria Sereno | 2020 | Cancer Biology & Medicine2020，17，2： | 4 |
| 8 | Flexible distributed feedback lasers based on nanoimprinted cellulose diacetate with efficient multiple wavelength lasing显示文摘Here we present the assembly of novel transparent all-polymer distributed feedback(DFB)lasers.Flexible and highly transparent cellulose diacetate(CdA)was employed as substrate on which gratings with different periods were engraved by thermal nanoimprinting with high fidelity.Highly luminescent conjugated polymers(CP),poly(9,9-dioctylfluorene)(PFO),poly(9,9-dioctylfluorene-alt-benzothiadiazole)(F8BT),and a blend of F8BT and poly(3-hexylthiophene)-poly(9,9-dioctylfluorene-altbenzothiadiazole)(P3HT:F8BT)were deposited by spin coating onto the nanostructured plastic surfaces,giving rise to perpendicular single-mode lasing emission in the blue,green,and red wavelength ranges,respectively.These lasers show linewidths below 1 nm and low thresholds(≈6μJcm^(−2) for blue and red lasing emission),comparable to other state-of-the-art lasers obtained from similar optical gain materials on rigid substrates.The followed strategy is scalable and versatile,enabling the development of large area nanoimprinted DFB lasers(>1cm^(2))on plastic,which is highly relevant for applications in various markets. | José R.Castro Smirnov Ahmad Sousaraei Manuel R.Osorio Santiago Casado Jaime J.Hernández Longfei Wu Qi Zhang Ruidong Xia Daniel Granados Reinhold Wannemacher Isabel Rodriguez Juan Cabanillas-Gonzalez | 2019 | npj Flexible Electronics2019，3，1： | 2 |
| 9 | Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study显示文摘 | M. Martin-Richard R. Gallego C. Pericay J. Garcia Foncillas B. Queralt E. Casado J. Barriuso V. Iranzo I. Juez L. Visa E. Saigi A. Barnadas X. Garcia-Albeniz J. Maurel | 2013 | Investigational New Drugs2013，，6： | 2 |
| 10 | Stable SREBP-1a knockdown decreases the cell proliferation rate in human preadipocyte cells without inducing senescence显示文摘 | María Soledad Alvarez Ana Fernandez-Alvarez Carme Cucarella Marta Casado | 2014 | Biochemical and Biophysical Research Communications2014，，1： | 2 |
| 11 | Could ivermectin have a synergic effect with albendazole in hydatidosis therapy?显示文摘 | N. Casado M. Moreno M. Urrea-París F. Rodríguez-Caabeiro | 2002 | Parasitology Research2002，，2： | 2 |
| 12 | In vitro effect of praziquantel and albendazole combination therapy on the larval stage of Echinococcus granulosus显示文摘 | M. A. Urrea-París M. J. Moreno N. Casado F. Rodriguez-Caabeiro | 2000 | Parasitology Research2000，，12： | 2 |
| 13 | Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study显示文摘 | Emilio Alba Manuel Ruiz-Borrego Mireia Margelí álvaro Rodríguez-Lescure Pedro Sánchez-Rovira Amparo Ruiz Jose Ramón Mel-Lorenzo Manuel Ramos-Vázquez Nuria Ribelles Elisa Calvo Antonio Casado Antonia Márquez David Vicente José Angel García-Sáenz Miguel Mar | 2010 | Breast Cancer Research and Treatment2010，，1： | 2 |
| 14 | Organometallics显示文摘 | Cuadrado I Morán M Casado C M | 1996 | 15:5 2781996，15，： | 1 |
| 15 | Infectious complications of percutaneous central venous catheterization in pediatric patients: a Spanish multicenter study显示文摘 | Garcia M A Casado F J Delgado M A | 2007 | Intensive Care Med2007，33，3： | 1 |
| 16 | UFT (tegafur -uracil)in rectal cancer 显示文摘 | Casado E Pfeiffer P Feliu J | 2008 | Ann Oncol2008，19，8： | 1 |
| 17 | Procalcitonin,A new marker for bacterial infection显示文摘 | CasadO F J Blanco Q | 2001 | An Esp Pediatr2001，54，： | 1 |
| 18 | Pilot scale mineralization of organic acids by electro-fenton process plus sunlight exposure显示文摘 | Juan Casado Jordi Fomaguera Maria Isabel Galan | 2006 | Water Research2006，40，： | 1 |
| 19 | Aniline degradation by electro-Fenton and peroxi-coagulation processes using a flow reactor for wastewater treatment 显示文摘 | Brillas E Casado J | 2002 | Chemosphere2002，47，3： | 1 |
| 20 | Equilibrium and stochastic resonance in finite chains of noisy bistable elements 显示文摘 | Manuel Morillo Jose Gomez-Ordonez Jose Manuel Casado | 2010 | Chemical Physics2010，375，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员